Used in scans for cervical and uterine cancer Ophthalmic angiography. ANDA 219139, held by Zydus Lifesciences. Indocyanine Green.
As of Nov 16, 2026, ANDA 219139 (Indocyanine Green), held by Zydus Lifesciences, was first approved by FDA on Aug 3, 2026, with 0 approved supplements and 0 published complete response letters.
Indocyanine green for injection is an optical imaging agent indicated for: Fluorescence imaging of vessels (micro-and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures, in adults and pediatric patients aged 1 month and older Fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older Fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer Ophthalmic angiography in adults and pediatric patients 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Indocyanine Green25MG/VIAL · injectable;injection | Indocyanine Green | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters